文献速递头颈甲状腺与浅表介入US

常规临床实践中经皮良性甲状腺结节射频消融的患者报告症状缓解

Patient-Reported Symptom Relief from Percutaneous Benign Thyroid Nodule Radiofrequency Ablation in Routine Clinical Care.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-04-02

回顾性队列纳入2021年5月12日至2024年8月7日在一家四级医院接受超声引导射频消融的症状性良性甲状腺结节成人患者49例,平均消融前结节体积30.6±31.0 mL;完成随访的36例中78.0%(28/36,95% CI 61.9%-88.3%)报告症状缓解,相对平均体积缩小52.3%±27%,症状缓解者体积缩小59% vs 未缓解者30%(P=.035)。

要点

  • 消融前常见症状为外观畸形37/49(77.1%)、吞咽困难28/49(58.3%)、发声困难15/49(30.6%)。
  • 完成随访者症状缓解率78.0%(28/36,95% CI 61.9%-88.3%),相对平均体积缩小52.3%±27%。
  • 症状缓解者体积缩小59% vs 未缓解者30%(P=.035),1例发生轻微出血并发症。

核心结论

  • 本诊所经皮超声引导热消融良性甲状腺结节的患者报告症状缓解约80%具有临床相关有效性,体积缩小率略低于疗效研究报道;本诊所患者结节体积大于已发表研究中的典型体积,且许多患者选择不做治疗后随访,可能低估了有效性和体积缩小测量。

研究设计与样本

  • 回顾性队列研究,纳入2021年5月12日至2024年8月7日在一家四级医院连续接受超声引导射频消融的症状性良性甲状腺结节成人患者49例(平均年龄56.6±13.1岁,女性45例),由单一委员会认证神经放射科医生采用经峡部移动射击技术操作,在6个月常规临床随访时评估患者报告症状缓解(症状缓解是/否),采用描述性统计,消融前结节大小与症状缓解的关联采用Wilcoxon检验。

诊断标准与关键数值

  • 症状缓解定义为患者报告症状缓解(是/否);完成随访的36例中症状缓解率78.0%(28/36,95% CI 61.9%-88.3%);相对平均体积缩小52.3%±27%,症状缓解者体积缩小59% vs 未缓解者30%(P=.035)。

临床应用与阅片要点

  • 作者认为,本诊所经皮超声引导热消融良性甲状腺结节的患者报告症状缓解约80%具有临床相关有效性,体积缩小率略低于疗效研究报道;本诊所患者结节体积大于已发表研究典型体积,且许多患者选择不做治疗后随访,可能低估有效性和体积缩小测量。

局限性

  • 本诊所患者结节体积大于已发表研究中的典型体积(平均消融前体积30.6±31.0 mL vs 近期Meta分析疗效研究的20.1±22.4 mL)。
  • 许多患者选择不做治疗后随访,仅36/49(73.0%)完成至少1次随访。
  • 上述因素可能低估了本诊所的有效性和体积缩小测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: We investigated patient-reported symptom relief from percutaneous ultrasound-guided radiofrequency ablation (RFA) of benign thyroid nodules in routine clinical care, given that prior studies have reported efficacy based on size reduction and specific symptom scores but not patient-reported effectiveness.

MATERIALS AND METHODS: This retrospective cohort study included all consecutive adults treated between May 12, 2021 and August 7, 2024 with ultrasound-guided RFA for symptomatic benign thyroid nodules at a quaternary care hospital. Procedures were performed by a single board-certified neuroradiologist utilizing a trans-isthmus moving shot technique. Patient-reported symptom relief (symptoms resolved yes/no) was assessed at 6-month routine clinical follow-up. Descriptive statistics were performed. Preablation nodule size associations with symptom resolution were assessed with Wilcoxon tests.

RESULTS: Forty-nine patients (mean age, 56.6 ± 13.1 years; 45 women) had average preablation nodule volume of 30.6 ± 31.0 mL, higher than the 20.1 ± 22.4 mL reported in a recent meta-analysis of efficacy studies. Common preablation symptoms were cosmetic deformity (37/49, 77.1%), dysphagia (28/49, 58.3%), and dysphonia (15/49, 30.6%). Thirty-six patients (73.0%) completed at least 1 follow-up visit. Postablation symptom resolution was 78.0% (28/36, 95% CI, 61.9%-88.3%) among those with follow-up, higher than the 64.4% reported in the single study included in the meta-analysis that assessed subjective symptom relief. Relative mean volume reduction was 52.3% ± 27% in those with follow-up and was associated with symptom resolution (59% reduction with symptom resolution versus 30% without; P = .035). One patient experienced a minor bleeding complication.

CONCLUSIONS: Patient-reported symptom relief from percutaneous ultrasound-guided thermal ablation of benign thyroid nodules in our clinic has resulted in approximately 80% clinically relevant effectiveness based on patient-reported symptom relief, with a slightly lower volume reduction rate compared with those reported in efficacy studies. Our clinic patients had larger nodule volumes than typical in published studies and many patients opted to forgo posttreatment follow-up. This likely led to underestimation of our effectiveness and volume reduction measurements.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Mai M, Levesque VM, Marqusee E, et al. Patient-Reported Symptom Relief from Percutaneous Benign Thyroid Nodule Radiofrequency Ablation in Routine Clinical Care. AJNR Am J Neuroradiol. 2026. PMID: 41015543. doi:10.3174/ajnr.A9022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。